- Home
- PEPG vs CERS Comparison
PEPG vs CERS Comparison
Compare PEPG & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- CERS
- Stock Information
- Founded
- PEPG 2018
- CERS 1991
- Country
- PEPG United States
- CERS United States
- Employees
- PEPG N/A
- CERS N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- PEPG Health Care
- CERS Technology
- Exchange
- PEPG Nasdaq
- CERS Nasdaq
- Market Cap
- PEPG 317.6M
- CERS 276.0M
- IPO Year
- PEPG 2022
- CERS 1997
- Fundamental
- Price
- PEPG $4.91
- CERS $1.65
- Analyst Decision
- PEPG Strong Buy
- CERS Buy
- Analyst Count
- PEPG 6
- CERS 1
- Target Price
- PEPG $9.17
- CERS $4.00
- AVG Volume (30 Days)
- PEPG 676.6K
- CERS 1.2M
- Earning Date
- PEPG 11-06-2025
- CERS 11-06-2025
- Dividend Yield
- PEPG N/A
- CERS N/A
- EPS Growth
- PEPG N/A
- CERS N/A
- EPS
- PEPG N/A
- CERS N/A
- Revenue
- PEPG N/A
- CERS $199,191,000.00
- Revenue This Year
- PEPG N/A
- CERS $19.07
- Revenue Next Year
- PEPG N/A
- CERS $12.03
- P/E Ratio
- PEPG N/A
- CERS N/A
- Revenue Growth
- PEPG N/A
- CERS 13.03
- 52 Week Low
- PEPG $0.88
- CERS $1.12
- 52 Week High
- PEPG $6.85
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- PEPG 56.79
- CERS 56.30
- Support Level
- PEPG $4.05
- CERS $1.38
- Resistance Level
- PEPG $4.89
- CERS $1.78
- Average True Range (ATR)
- PEPG 0.40
- CERS 0.10
- MACD
- PEPG -0.07
- CERS 0.01
- Stochastic Oscillator
- PEPG 51.90
- CERS 63.75
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.